You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The medical policy update makes the unnamed insurer the first commercial plan to cover ThyraMIR, a microRNA gene expression classifier launched earlier this year.
The change makes Anthem one of the first major payors to say that NIPT is medically necessary for the non-high-risk pregnancy population.
Through the arrangement, Paradigm's test, which sequences both DNA and RNA, will be available to the more than 15 million US members in Three River's network.
The tool is aimed at facilitating a simple and efficient process that payors can use to asses a CDx's value and if further technology assessments are warranted.
Stratose and Paradigm have inked a deal providing Stratose's members access to the PCDx test, which uses NGS technology to identify genomic and proteomic mutations.
Health Net's coverage of Biodesix's proteomic test for non-small cell lung cancer follows similar decisions last month by Aetna and Cigna.
OKP will pay for testing if standard first trimester screening indicates a risk higher than 1:1000 for trisomies 21, 18, or 13.
Aetna is the first major commercial insurer to cover Interpace's ThyGenX and brings the total number of covered lives for it to more than 100 million.
The test differentiates benign thyroid nodules from cancerous ones.
The company has received similar coverage decisions from other payors in recent months.
NPR reports that researchers have developed chimeric embryos as part of work toward growing human organs in animals for organ transplants.
According to the Washington Post, the Biden Administration is set to make changes to federal restrictions on fetal tissue research.
In Science this week: approach to isolated trace DNA from archaic humans from sediments, and more.
Texas Monthly looks into the DNA Zoo being collected by Baylor College of Medicine researchers.